BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Deloitte
Chubb
Federal Trade Commission
Baxter
Citi
Farmers Insurance
UBS
Express Scripts
Covington

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021949

« Back to Dashboard

NDA 021949 describes PULMICORT FLEXHALER, which is a drug marketed by Astrazeneca and is included in one NDA. It is available from three suppliers. There are four patents protecting this drug. Additional details are available on the PULMICORT FLEXHALER profile page.

The generic ingredient in PULMICORT FLEXHALER is budesonide. There are twenty drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the budesonide profile page.
Summary for 021949
Pharmacology for NDA: 021949
Medical Subject Heading (MeSH) Categories for 021949
Suppliers and Packaging for NDA: 021949
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949 NDA AstraZeneca Pharmaceuticals LP 0186-0916 0186-0916-12 1 INHALER in 1 CARTON (0186-0916-12) > 120 AEROSOL, POWDER in 1 INHALER
PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949 NDA AstraZeneca Pharmaceuticals LP 0186-0917 0186-0917-06 1 INHALER in 1 CARTON (0186-0917-06) > 60 AEROSOL, POWDER in 1 INHALER

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER, METERED;INHALATIONStrength0.08MG/INH
Approval Date:Jul 12, 2006TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Jan 9, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
Patent:➤ SubscribePatent Expiration:May 8, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ SubscribePatent Expiration:Jan 9, 2018Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021949

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949-001 Jul 12, 2006 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949-002 Jul 12, 2006 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949-002 Jul 12, 2006 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949-002 Jul 12, 2006 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949-001 Jul 12, 2006 ➤ Subscribe ➤ Subscribe
Astrazeneca PULMICORT FLEXHALER budesonide POWDER, METERED;INHALATION 021949-001 Jul 12, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Cipla
McKesson
Boehringer Ingelheim
Fuji
Queensland Health
Chinese Patent Office
AstraZeneca
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot